Related Experiment Video
Updated: Jun 21, 2025

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Tumor Mutational Load: A Novel Predictor for Clinical Benefit of Pembrolizumab
Fang-Chi Hsu1, Yun Yen2,3
1Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts.
Abstract:
A recent study evaluated the efficacy of pembrolizumab across various cancers, classified according to tumor mutational load (TML) defined by whole-genome sequencing. Tumors exhibiting intermediate to high TML showed improved clinical benefit from pembrolizumab. This proof-of-concept study highlights clinical value of TML in patient selection, advancing precision immunotherapy and treatment strategies. See related article by Geurts et al., p. 3735.
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
Abnormal Proliferation
Tumor Immunotherapy